Dr Reddys Laboratories (RDY) EPS (Diluted) Growth (3y) (2012 - 2026)
Powered by 
Analysis
Dr Reddys Laboratories (RDY) EPS (Diluted) Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.63 Bn | 38.97 Bn | 2.15 Bn | 15.17% |
| 2 | Viatris | 19.19 Bn | 18.30 Bn | 1.46 Bn | -35.09% |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | -34.96% |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.35 Bn | 334.51 Mn | 40.23% |
| 5 | Bausch Health Companies | 2.36 Bn | 520.30 Mn | 2.10 Bn | 110.67% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 51.05% |
| 8 | Amphastar Pharmaceuticals | 995.52 Mn | 705.40 Mn | 93.47 Mn | 11.31% |
| 9 | Fennec Pharmaceuticals | 404.35 Mn | 363.10 Mn | 17.15 Mn | 31.36% |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -34.96% |
| Mar 31, 2026 | -71.30% |
| Dec 31, 2025 | -55.08% |
| Sep 30, 2025 | 2.62% |
| Jun 30, 2025 | 2.36% |
| Mar 31, 2025 | -97.08% |
| Dec 31, 2024 | 51.53% |
| Sep 30, 2024 | 17.15% |
| Jun 30, 2024 | 7.50% |
| Mar 31, 2024 | 26.81% |
| Dec 31, 2023 | 30.14% |
| Sep 30, 2023 | 290.55% |
| Jun 30, 2023 | 17.73% |
| Mar 31, 2023 | 28.77% |
| Dec 31, 2022 | 15.94% |
| Sep 30, 2022 | 58.72% |
| Jun 30, 2022 | 0.19% |
| Mar 31, 2022 | -42.63% |
| Dec 31, 2021 | -8.69% |
| Sep 30, 2021 | 9.90% |